Background. Genital wart (GW) incidence is high among men. The percentage and rate at which subsequent GW events occur are understudied. The purpose of this study was to describe the rate of subsequent GWs, associated human papillomavirus (HPV) types, and time to subsequent GW event among unvaccinated men.
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide [1] . Most HPV infections clear on their own; however, persistent infection is strongly associated with risk of HPV-related cancers among both men and women. HPV causes penile, oropharyngeal, and anal cancer in men and cervical, vulvar, anal, and oropharyngeal cancer in women [2] . . Additionally, HPV causes noncancerous external genital lesions, called condylomata acuminatum, commonly referred to as condyloma or genital warts. Genital warts are a common outcome of HPV infection. HPV types 6 and 11 are the most frequently detected types in genital warts [3, 4] . Factors associated with the incidence of genital warts in men include younger age (<30 years) and high lifetime number of sexual partners [5, 6] . An estimated $200 million is spent annually in the United States for genital wart treatment, which is often ineffective [6, 7] . Previously, we demonstrated that genital HPV infection prevalence and incidence remains constant across the life span of men. In addition, we demonstrated that genital wart incidence is high in men, regardless of country studied, and continues to occur in middle-aged and older men [8] . What has remained unclear is the total genital wart burden-that is, the incidence of a first event and the rate at which subsequent genital wart events occur among men. The purpose of the current study was to describe the rate at which genital warts recur and the HPV types associated with these events, as well as the time between the detection of the first primary lesion to the detection of the subsequent genital wart event in an unvaccinated population of men.
METHODS

Study Population
The current study was nested within the HPV Infection in Men (HIM) Study, a multinational prospective HPV natural history study of men in 3 countries. HIM Study participants are men aged 18-70 years living in Tampa, Florida; Cuernavaca, Mexico; and São Paulo, Brazil, enrolled between July 2005 and June 2009. A full description of study procedures has been previously published [9, 10] . In brief, participants were seen every 6 months for a physical examination, sample collection, and a survey for up to 7 years of follow-up. Men were recruited from 3 different population sources-the general population, universities, and organized healthcare systems (Mexico only)-to increase access to men with a broad range of ages, sexual behaviors, and HPV risk. In Brazil, men were recruited from the general population at a facility for urogenital care (Centro de Referencia e Tratamento de Doencas Sexualmente Transmissiveis e AIDS) and through general media advertising. Men presenting for non-sexually transmitted infection-related conditions were enrolled in the present study. In addition, the spouses and partners of women participating in a large cohort study of the natural history of HPV infection and risk of cervical neoplasia conducted in São Paulo since 1993 were also recruited. At the Cuernavaca, Mexico site, the underlying population was comprised of employees and beneficiaries of the Instituto Mexicano del Seguro Social, factory employees, and officials of the Mexican army that were permanently assigned to this geographic area. In the United States, the underlying population was from the University of South Florida and the greater Tampa metropolitan area. Flyers and posters were distributed throughout the campus and community, and monthly educational presentations were also given. In addition, men from the broader Tampa Bay, Florida, community were recruited through the mail and media using brochures and flyers, as well as advertisements in local and university papers. Men 18-70 years of age who reported no prior diagnosis of penile or anal cancers, no symptoms of a sexually transmitted infection or treatment for a sexually transmitted infection, had not participated in an HPV vaccine study, had no history of human immunodeficiency virus or AIDS, had no history of imprisonment, homelessness, or drug treatment during the past 6 months, and were willing to comply with 10 scheduled visits (every 6 months for 4 years) were included in the study.
Participants were assessed every 6 months for a median follow-up of 50.4 months (range, 5.0-129.2 months). If the participant noted the appearance of genital lesions in between study visits, they were instructed to call and make an appointment for a clinic visit with the study team. As such, some lesions were diagnosed prior to the first 6-month study visit and between visits subsequent to the first 6-month follow-up visit. A total of 4123 men enrolled in the HIM Study and were included in this study. At every study visit a clinician conducted a physical examination, which included a detailed external examination of the abdominal, penile, anal, rectal, testicular, and inguinal areas.
An extensive sexual history and health questionnaire given at each visit assessed sociodemographic characteristics, sexual and contraceptive history, condom use practices, alcohol and tobacco use, and history of abnormal pap smears in female partners. The questionnaire required approximately 20 minutes to complete and was administered using computer-assisted self-interviewing.
Genital Wart Sampling and HPV Genotyping
External genital lesions, predominantly genital warts, which appeared to be HPV-related or had an unknown etiology based on visual inspection were sampled by a Dacron swab, stored in standard transport medium (STM), and genotyped for HPV using linear array. Lesions that were clearly not HPV related and had distinct features of other types of lesions, such as herpes simplex virus, pearly penile papules, and Molluscum contagiosum were not sampled.
The clinician used a 3× magnification to look for the presence of genital warts and other HPV-related lesions. Circumcision status, and the presence, location, and size of lesions, ectoparasites, erythema, abrasions, rashes, inflammation, discharges, tenderness, and/or adenopathy were noted. In addition, the clinician recorded whether the subject had genital piercing or genital tattoos, and if he shaved the genital area. If, during the visual physical examination, genital warts were detected, the clinician sampled these prior to the sampling of normal penile skin. The clinical impression was noted to include one of the following: condyloma acuminatum (genital wart), bowenoid papulosis, squamous cell carcinoma in situ, or other infectious or malignant process. In the case where multiple warts were observed, the one wart that was most representative of the morphology, suspicious for the suspected diagnosis, or anatomic location was selected. A second swab was obtained if a wart was identified in a separate anatomic site or a wart was identified with different morphology in the same anatomic location. Different swabs were used for each wart to prevent cross-contamination. An exfoliated cell specimen was collected from the surface of each wart by wetting a Dacron applicator with sterile normal saline, and placing the swab in buffered preservative solution designed to preserve DNA, RNA, and protein (STM).
All samples were stored at -80°C until HPV genotyping. Samples underwent DNA extraction using the QIAamp DNA Mini Kit (Qiagen, Valencia). In brief, 200-μL aliquots of samples were digested with 20 μL of proteinase K solution for 1 hour at 65°C, followed by 200 μL of lysis buffer. Polymerase chain reaction (PCR) analysis was performed within 36 hours after extraction. Samples were tested for the presence of HPV, using the PCR consensus primer system (PGMY 09/11) [11] . HPV genotyping was conducted using the linear array assay (Roche Diagnostics) by amplifying 50 μL of the DNA extracts to detect 36 HPV types. All plates included negative controls (nontemplate controls) and positive controls (CaSki) to control for possible contamination. Only samples that tested positive for β-globin or an HPV genotype were considered adequate and included in the analysis. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 were classified as high risk, and HPV types 6, 11, 26, 34, 40, 42, 44, 53, 54, 61, 62, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, and 89 were classified as low risk. HPV genotyping was performed in a central laboratory location to reduce bias in testing methodologies.
Statistical Analyses
A subsequent genital wart event was defined as genital warts detected following the previous event by 16 weeks (112 days) or more. Descriptive statistics included generating frequency distributions for categorical variables and mean, median, standard deviation, and confidence intervals (CIs) for continuous variables, were conducted.
Among men with a prevalent or incident genital wart, the overall incidence rate of a subsequent genital wart event was estimated for the cohort as a whole as well as by country, age, and smoking status. Incidence rates were estimated from the total number of events divided by the total at-risk population. The 95% CIs were calculated from the incident events and person-time, and followed a Poisson distribution. Person-time was calculated as time from date of the previous genital wart event until date of next event, or until last known date seen on study. Fisher exact test was used to assess statistical significance in prevalence and incidence of subsequent genital wart events differences by sociodemographic variables. Subsequent genital wart events were further classified as recurrent (defined as any wart with the same HPV type in the same location as the prior genital wart) or new (defined as a subsequent genital wart that occurred at either a different anatomic location or with a different HPV type).
A time-to-event approach was applied using the KaplanMeier estimator of the survival function to assess time to the first subsequent genital wart event overall and by country. The analytical unit for this study was the person, and all analyses were performed using SAS version 9.4 software.
RESULTS
A total of 4123 men 18-70 years of age comprised the HIM Study cohort (1353 from the United States, 1412 from Brazil, and 1358 from Mexico), of which 610 (14.8%) developed at least 1 genital wart during follow-up. Among these men, 566 (93.0%) (195 from the United States, 132 from Brazil, and 239 from Mexico) had complete HPV genotyping results and were included in this analysis.
Demographic, behavioral, and health characteristics of men at the time of the first detected genital wart are presented in Table 1 . The majority (46.3%) of men who developed a genital wart were 18-30 years of age, with the mean age at the time of the initial genital wart diagnosis of 33.3 (standard deviation, 10.6) years. A similar percentage reported white (40.3%) and Mexican (39.0%) race/ethnicity, and 14.7% and 4.2% reported black and Asian/Pacific Islander race/ethnicity, respectively. Approximately 59% of men were not circumcised, 47.2% were married or cohabiting, 42.0% reported having >15 years of education, 62.7% reported having >5 lifetime female sex partners, and 33.6% reported having >1 female sexual partner during the past 3 months. Approximately 10% reported having at least 1 male sexual partner in their lifetime, and 71.4% of those reported at least 1 male partner in the past 3 months.
Overall, 86.6% of the initially detected genital warts were HPV positive, with the majority positive for either HPV-6 (44.2%) or HPV-11 (10.1%). More than 60% of the genital warts were positive for at least 1 of the HPV types included in the 4-valent vaccine (HPV types 6, 11, 16, 18) , and 65.7% tested positive for at least 1 of the 9 HPV types included in the 9-valent vaccine (HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58).
Of the 566 men with a genital wart event, 251 (44.3%) had 1 or more subsequent genital wart events detected, 125 (22.1%) had 2 subsequent events, 62 (11.0%) had 3 subsequent events, and 37 (6.5%) had ≥4 subsequent warts detected ( Table 2 ). The proportion of men with subsequent genital wart events did not differ by the HPV type of the initial genital wart, age at the index genital wart, or smoking status; however, significant differences in the proportion of men with repeated genital wart events were detected by country (P = .0059), with men in Brazil having the lowest proportion of subsequent events (37.1%), followed by men in Mexico (41.0%). Men in the United States had the highest proportion of subsequent genital wart events (53.3%) and the highest proportion of ≥4 subsequent genital wart events (9.7%). Table 3 presents the incidence of subsequent genital wart events for each subsequent event and by initial genital wart HPV type, participant age, country, and smoking status. Overall, the rate of 1 subsequent genital wart event was 13.1/1000 person-months. As with prevalence, the incidence of subsequent genital wart events was lowest among men in Brazil. The incidence of a second subsequent genital wart event was 20.4/1000 person-months. Among men with multiple subsequent genital wart events, the incidence of subsequent events increased with each subsequent event (ie, incidence rate of 24.7 and 36.6/1000 person-months for the third and fourth subsequent genital wart events, respectively). In general, this trend did not vary by country, age, or smoking status, indicating that men with 1 subsequent genital wart event are at high risk of multiple subsequent genital wart events regardless of sociodemographic characteristics. However, among men with 4 subsequent genital wart events, the incidence of genital warts was highest among men >40 years of age (71.4/1000 person-months) compared to men aged 18-30 years and men aged 31-40 years (26.6 and 54.4/1000 person-months, respectively).
As shown in Table 4 , the proportion of genital warts positive for HPV-6 and/or -11 remained relatively constant across the multiple genital wart events. Approximately 63%-69% of genital wart events had presence of 1 of more HPV types the 9-valent HPV vaccine is directed against. The proportion of men with subsequent genital wart events that were classified as recurrent (same HPV type at same anatomic location) or as new (subsequent genital wart that occurred at either a different anatomic location or with a different HPV type).by subsequent event is presented in Figure 2 . At the first subsequent genital wart event, 43% were recurrent events. The proportion of recurrent events significantly declined, with each subsequent event decreasing to 12.5% at the seventh subsequent genital wart event, and a concomitant rise in the proportion of new genital wart events was observed.
DISCUSSION
This is the first report of genital wart recurrence among a cohort of men closely examined for genital HPV infection natural history. We observed a high rate of repeated episodes of genital warts, with 44.3% of men experiencing 1 or more episodes of genital warts following the initial episode. Men with ≥2 subsequent events were at highest risk of continued experiences with genital warts, as high as 10 postinitial disease events. These data highlight the high burden of genital wart disease among men across the lifespan internationally. Previously we reported the incidence of genital warts among men in Brazil, Mexico, and the United States documenting a high rate of progression of genital HPV-6 and -11 infections to disease and relatively constant incidence rate across countries (1.6-1.9/100 person-years) [8, 12] . The prior research only examined the first genital wart diagnosis. What has remained unclear is the rate at which men experience multiple genital wart episodes. In a retrospective chart review study from Canada [13] , 46.8% of men experienced 1 or more genital wart events subsequent to the index diagnosis, and 3.2% experienced a fourth subsequent genital wart event. In the current study where men were physically examined every 6 months, we observed a similar proportion of men experiencing 1 or more subsequent genital wart events (44.3%). However, up to 10 subsequent genital wart events were observed, with 6.5% experiencing ≥4 subsequent events. The differences in study findings are likely due to the increased surveillance of the HIM Study compared to a study that relied on men self-referring for clinical care.
When examining factors associated with a first genital wart episode, we observed a decline in genital wart incidence with age, although older men continued to experience a new diagnosis. However, among men in Mexico, genital wart incidence did not significantly decrease with age [8, 12] . In contrast to the first genital wart event, we did not observe significant differences in the proportion of men diagnosed with subsequent genital warts by age group, nor did we observe differences in genital wart incidence of subsequent events by age. The factor most strongly associated with multiple subsequent events was having ≥2 subsequent events. The incidence of each subsequent genital wart event increased with increasing events. For example, the incidence of a first subsequent event was 13.1/1000 person-months compared with 36.6/1000 person-months for the fourth subsequent event, among men who experienced a third subsequent event. Sexual behavioral factors associated with the incidence of genital warts likely explain each subsequent genital wart event, identifying a group of men at highest risk of repeated disease.
A smaller proportion of men in Brazil experienced multiple genital wart events compared with men residing in Mexico and the United States, although the incidence of the first genital wart was not different for men in Brazil compared to the 2 other countries [8] . As each country participating in the HIM Study implemented the same physical examination study procedures, it is unlikely that differences in diagnoses by country occurred. One explanation is that differences in the standard of care for genital warts underlie this observation; in Brazil excision is the preferred treatment modality compared with topical treatment in the United States and Mexico. Another potential explanation is that the first genital wart experience altered the sexual behavior of men in Brazil to a greater extent than among men in the United States and Mexico. Additional research is needed to discern the multiple factors that contribute to repeated genital wart diagnoses among men, and differences by country. This is the first study to distinguish genital wart recurrence (same HPV type and location) from new subsequent genital wart events. The proportion of subsequent events classified as recurrent ranged from 39%-43% for the first 3 subsequent events and subsequently declined to 27% for the fourth event and further to 0% by the seventh event. What is unclear is whether recurrence of an event with the same HPV type and anatomic location represents treatment failure or reacquisition of the same HPV type and progression to a new genital wart episode. We previously demonstrated a very low rate of seroconversion following HPV-6 and -11 infection [14] and no protection conferred among men who are HPV-6 or -11 seropositive [15, 16] . Given the median time to subsequent genital wart event of 73.4 months, it is possible that infection reacquisition of the same HPV type and disease progression occurred, given that few men seroconvert following infection and, among those that do seroconvert, protection against subsequent infection has not been observed.
Strengths of this study include the inclusion of a large sample size of men closely followed clinically with a common protocol for up to 10 years of follow-up in 3 countries. The occurrence of study visits every 6 months allowed for detection of genital warts that may have gone undetected or detected at later times in the absence of surveillance. Careful annotation of genital wart anatomic location and HPV type allowed for a distinction between a possible recurrent event and a new event. There are study limitations that also need to be considered in interpreting these results. The current study utilized the clinician diagnosis of genital warts and not histology to define the diagnosis, a method most countries utilize clinically to inform treatment. However, this procedure may have misidentified lesions as genital warts, or underestimated HPV prevalence as only 86.6% of the first detected wart was HPV positive. In a prior study of surface of genital wart vs intrawart HPV typing, we reported a significantly higher prevalence of HPV-6 and -11 within the wart compared to the surface [17] . Therefore, both the proportion of genital warts due to HPV-6 and -11 and estimate of subsequent genital wart events may have been underreported here.
In conclusion, the percentage of men with multiple genital wart events is high and remains high across the lifespan, most of which is attributable to HPV-6 and -11 infections. Studies from Australia, Canada, and the United States show dramatic declines in genital wart prevalence subsequent to HPV vaccine program implementation [18] [19] [20] . As genital warts are lesions associated with high rates of HPV transmission [4, 21] , vaccination of males against HPV represents an important public health strategy to reduce the large burden of HPV-related diseases in men as well as among their sexual partners [22, 23] . 
